Adverse Effects of Treatment with Intravenous Immunoglobulins for Neurological Diseases

Overview

Journal J Neurol

Specialty Neurology

Date 2006 Sep 26

PMID 16998759

Citations 6

Authors

Matthias Wittstock

Uwe K Zettl

Affiliations

Soon will be listed here.

Abstract

Therapy with intravenous immunoglobulins (IVIg) is considered to be a safe treatment for a number of immune-mediated neurological diseases. Published data about prevalence of adverse effects range from 11 to 81%. The purpose of our study was to preserve a representative view on adverse effects by analysis of a large cohort of patients treated by IVIg. A recent prospective study reported 42.7% adverse events. The majority of patients presented with minor adverse effects, mostly asymptomatic laboratory changes. Rash or mild headache occurred especially when IVIg was administered with an infusion flow higher than 10 g/h. Severe complications like deep vein thrombosis or others are rare. In addition to its efficacy, IVIg therapy appears to be a safe therapy in immune-mediated neurological diseases. Most patients show no or minor adverse effects. Patients with pre-existent disorders like heart or renal insufficiency or immobilized patients, however, may be at higher risk for complications.

Citing Articles

Multiple cerebral infarctions after intravenous immunoglobulin for Guillain-Barré syndrome: two case reports and review of the literature.

Wang W, Feng C, Liu Y, Tao Y, Bi X, Hou X Front Immunol. 2024; 15:1433240.

PMID: 39108266 PMC: 11300209. DOI: 10.3389/fimmu.2024.1433240.

Consider Alternative Causes of Death to SARS-CoV-2 Vaccination-Related Guillain-Barre Syndrome without Dysautonomia.

Finsterer J Ann Indian Acad Neurol. 2023; 25(6):1223.

PMID: 36911433 PMC: 9996477. DOI: 10.4103/aian.aian_585_22.

Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions.

Klemencic Kozul T, Yudina A, Donovan C, Pinto A, Osman C BMC Health Serv Res. 2022; 22(1):904.

PMID: 35831856 PMC: 9277970. DOI: 10.1186/s12913-022-08210-z.

Protective effects of cultured and fermented ginseng extracts against scopolamine-induced memory loss in a mouse model.

Han S, Kim S, Yun Y, Nam S, Lee H, Lee B Lab Anim Res. 2018; 34(1):37-43.

PMID: 29628975 PMC: 5876162. DOI: 10.5625/lar.2018.34.1.37.

Clinical and economic outcomes of a "high-touch" clinical management program for intravenous immunoglobulin therapy.

Zhu J, Kirkham H, Ayer G, Chen C, Wade R, Karkare S Clinicoecon Outcomes Res. 2018; 10:1-12.

PMID: 29296090 PMC: 5741071. DOI: 10.2147/CEOR.S142239.

References

Dalakas M . Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve. 1999; 22(11):1479-97. DOI: 10.1002/(sici)1097-4598(199911)22:11<1479::aid-mus3>3.0.co;2-b. View

Wittstock M, Benecke R, Zettl U . Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol. 2003; 50(3):172-5. DOI: 10.1159/000073059. View

Hahn A . Intravenous immunoglobulin treatment in peripheral nerve disorders--indications, mechanisms of action and side-effects. Curr Opin Neurol. 2000; 13(5):575-82. DOI: 10.1097/00019052-200010000-00012. View

Frank M, Basta M, Fries L . The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol. 1992; 62(1 Pt 2):S82-6. DOI: 10.1016/0090-1229(92)90045-p. View

Dalakas M . High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994; 44(2):223-6. DOI: 10.1212/wnl.44.2.223. View

. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. The Dutch Guillain-Barré Study Group. Ann Neurol. 1994; 35(6):749-52. DOI: 10.1002/ana.410350618. View

Sekul E, Cupler E, Dalakas M . Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994; 121(4):259-62. DOI: 10.7326/0003-4819-121-4-199408150-00004. View

Silbert P, Knezevic W, Bridge D . Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology. 1992; 42(1):257-8. DOI: 10.1212/wnl.42.1.257. View

Hamdalla H, Hawkes C, Spokes E, Bamford J, Goulding P . Intravenous immunoglobulin in the Guillain-Barré syndrome. May cause severe adverse skin reactions. BMJ. 1996; 313(7069):1399-400. PMC: 2352928. DOI: 10.1136/bmj.313.7069.1399c. View

10.

Wiles C, Brown P, Chapel H, Guerrini R, Hughes R, MARTIN T . Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry. 2002; 72(4):440-8. PMC: 1737833. DOI: 10.1136/jnnp.72.4.440. View

11.

Stangel M, Kiefer R, Pette M, Smolka M, Marx P, Gold R . Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study. J Neurol. 2003; 250(7):818-21. DOI: 10.1007/s00415-003-1085-1. View

12.

Vucic S, Chong P, Dawson K, Cudkowicz M, Cros D . Thromboembolic complications of intravenous immunoglobulin treatment. Eur Neurol. 2004; 52(3):141-4. DOI: 10.1159/000081465. View

13.

Sinclair N . Fc-receptor-mediated immunomodulation. Immunol Today. 1991; 12(1):46. DOI: 10.1016/0167-5699(91)90113-8. View

14.

Stangel M, Hartung H, Marx P, Gold R . Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci. 1998; 153(2):203-14. DOI: 10.1016/s0022-510x(97)00292-x. View

15.

Basta M, Kirshbom P, Frank M, Fries L . Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest. 1989; 84(6):1974-81. PMC: 304080. DOI: 10.1172/JCI114387. View

16.

Go R, Call T . Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc. 2000; 75(1):83-5. DOI: 10.4065/75.1.83. View

17.

Burks A, Sampson H, Buckley R . Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med. 1986; 314(9):560-4. DOI: 10.1056/NEJM198602273140907. View

18.

Brannagan 3rd T, Nagle K, Lange D, Rowland L . Complications of intravenous immune globulin treatment in neurologic disease. Neurology. 1996; 47(3):674-7. DOI: 10.1212/wnl.47.3.674. View

19.

Frank M, Miletic V, Jiang H . Immunoglobulin in the control of complement action. Immunol Res. 2001; 22(2-3):137-46. DOI: 10.1385/IR:22:2-3:137. View

20.

Wada J, Shintani N, Kikutani K, Nakae T, Yamauchi T, Takechi K . Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin Exp Immunol. 2001; 124(2):282-9. PMC: 1906047. DOI: 10.1046/j.1365-2249.2001.01499.x. View